New drug cocktail aims to fight Hard-to-Treat cancers

NCT ID NCT06953323

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called WJB001 combined with various chemotherapy drugs in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose, check how the body processes the drug, and see if it shrinks tumors. About 86 participants will be enrolled, and the goal is to determine if this combination is safe and worth further study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

WJB001 (Wee1 inhibitor) combined with chemotherapy drugs like paclitaxel, carboplatin, or other targeted agents

What this could lead to

If successful, this could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapies.

What could go wrong

This is an early-phase trial with a small number of participants, so the results may not apply to everyone. The combination therapy may cause significant side effects, and it is too soon to know if it will work better than existing treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial serous adenocarcinoma fallopian tube cancer neoplasm ovarian serous adenocarcinoma peritoneum cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cancer Hospital Chinese Academy of Medical Sciences

    RECRUITING

    Beijing, Beijing Municipality, 100021, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

  • Fujian Cancer Hospital

    RECRUITING

    Fuzhou, Fujian, 350000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Hunan Cancer Hospital

    RECRUITING

    Changsha, Hunan, 410000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Liaoning Cancer Hospital

    RECRUITING

    Shenyang, Liaoning, 110000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Sun Yat-sen Hospital, Sun Yat-sen University

    RECRUITING

    Guangzhou, Gunagdong, 510000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Sun Yat-sen University Cancer Center

    RECRUITING

    Guangzhou, Guangdong, 510000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The First Affiliated Hospital of China Medical University

    RECRUITING

    Shenyang, Liaoning, 110000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Tumor Hospital Affiliated to Guangxi Medical University

    RECRUITING

    Nanning, Guangxi, 530000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, 430023, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact